There is renewed interest in high-dose vitamin C interventions in clinical medicine due to its antioxidant properties, safe use and cost-effectiveness. Yet, randomised control trials (RCTs) employing these interventions are failing to include robust analytical methodology and proper sample handling and processing techniques. Consequently, comparisons between studies becomes impossible as there is no metrological traceability and results may be prone to pre-analytical errors.
Through published vitamin C stability studies, method comparison papers and data from vitamin C external quality assurance programs, an assessment was made on the functionality of current methods for critically ill patient samples.
Data was obtained from two external quality assurance programs, two papers assessing sample stability and interlaboratory agreement and a publication on vitamin C method comparisons. A shift from spectrophotometric and enzymatic methodologies to high performance liquid chromatography (HPLC) greatly improved the variability and interlaboratory agreement. Therefore, the current analytical performance of vitamin C HPLC methodologies are acceptable for the requirements of a high-dose vitamin C RCTs.
Recommendations across the total testing process of vitamin C have been provided to improve the quality of the results. The harmonisation of sample handling and processing procedures will further improve the reliability of current analytical methodologies.
Vitamin C, or ascorbic acid (literally “against scurvy”), is well described in the popular literature for its role as an antioxidant. Vitamin C is also involved in gene expression as well as various cellular metabolic processes in a non-antioxidant role . It is a water-soluble vitamin that is naturally present in some foods and is added to others as well as being available as a dietary supplement. Humans, unlike most animals, are unable to synthesize vitamin C endogenously, so must obtain it from their diet. Anecdotal evidence regarding the effectiveness of high-dose vitamin C on health has led to renewed interest in clinical medicine, which is highlighted in an intervention strategy for critical care patients with septic shock .
We have identified 29 trials conducted over the last decade employing vitamin C interventions in critically ill patients, with many using doses of ≥2.0 g/day. These trials are composed of 23 randomised control trials (RCTs) , , , , , , , , , , , , , , , , , , , , , , , two prospective ,  and four retrospective analyses , , , . Of these, 21 reported a variety of clinical benefits when an antioxidant supplementation protocol was implemented , , , , , , , , , , , , , , , , , , , , ; six included an analytical method for vitamin C in their protocol , , , , , ; five included the analysis of vitamin C post dose , , , ,  and a single RCT included a sample handling and processing protocol as well as the stability of the analyte . A significant variation exists in the analytical design of these studies (Figure 1, Supplementary Material 1).
The inclusion of vitamin C analysis in these trials was to: (1) determine the prevalence of hypovitaminosis in their study cohort, and therefore justify supplementation; (2) ensure that the dosing regimen was sufficient to return vitamin C levels to normal , , ; (3) and/or to monitor the effects the concentrations had on the Sequential Organ Failure Assessment (SOFA) scores, endothelial function, soluble adhesion molecules, oxidative stress and/or inflammatory markers , . However, the majority of the studies (79%) are missing a key component by not including the distribution and clearance of vitamin C in blood and tissue to correlate the clinical outcomes to the intervention.
Methodology is a key factor in producing reliable vitamin C results. With clinical medicine moving towards high-dose vitamin C therapy, the analytical side of vitaminology may need to accommodate for this trend. Considerations for vitamin C analysis span the total testing process from stability of the sample, understanding the measurand, through to interpretation against reference data. The harmonisation of these processes would ensure that all laboratories have an appropriate protocol in place and that interpretation of the data is consistent.
In this article, we evaluated the current vitamin C measurement methodologies and critically assessed their use for trials involving high-dose vitamin C administration in the critically ill patient population.
Original, full-text, articles published in peer-reviewed journals were compiled through electronic searching of the Embase, Medline and PubMed databases. The search keywords included ascorbic acid, ascorbate, vitamin C as well as terms related to the comparison of analytical methodologies such as analysis, method, measure or measurement, comparison, evaluation and assessment. To further refine the search, the terms serum and plasma were included as search keywords, study types were limited to human only and the date of publication was limited from 2008 to current. This period encompasses the beginnings of the introduction of vitamin C into the Royal College of Pathologists Australasia Quality Assurance Program (RCPAQAP). Through these search parameters only a single publication on direct vitamin C method comparisons was identified.
The physiology and pathophysiology of vitamin C has been extensively covered in both its antioxidant and non-antioxidant roles , , , . Thus, it will only be lightly discussed here. Vitamin C is a water-soluble vitamin, which has been estimated to have a plasma half-life of 7–14 days . However, these values are based on healthy males subjected to depletion-repletion cycles and so may not reflect the half-life in critically ill populations , , , . In addition, vitamin C is absorbed through the intestines; therefore there are saturable absorption limits (~0.4 g) which will reduce the bioavailability of higher enteral doses , .
Low blood vitamin C levels are considered to be caused by either a reduced intake (e.g. deprivation of fresh fruits and vegetables) or an increased rate of depletion or intracellular uptake (or redistribution) which occurs following trauma or infection , , , . Increased distribution is associated with high leukocyte turnover (as there is a high intracellular vitamin C concentration in these cells), and oxidative stress, where the redox attributes of vitamin C reduces the impact of reactive species attenuating its antioxidant properties via hydrolysis to 2,3-diketogulonic acid (Figure 2) , .
Patients in the intensive care unit (ICU) have been shown to have a high prevalence of low vitamin C levels (11.0–23.0 μmol/L) and so are at risk of developing blood levels similar to those seen with vitamin C deficiency (<11.0 μmol/L) , , . Low vitamin C levels are thought to be associated with higher SOFA scores and increased mortality . Oxidative stress is believed to be one of the primary causes of vitamin C deficiency in ICU patients. This is also true for patients outside of the ICU setting . Its prevalence is elevated in sepsis, trauma, infection, haemorrhage, multiple organ failure, stroke, cardiac disease and ischemic tissue injury from cardiac surgery , , , , , , . Many of these illnesses have a high risk of morbidity and mortality as well as increased length of stay in the ICU and hospital , . High-dose vitamin C supplementation may reduce oxidative damage through neutralising the reactive species and stopping or decreasing lipid peroxidation, improving tissue perfusion, tissue oxygenation (avoiding hypoxia) and alleviating potential organ dysfunction . Additionally, a range of positive outcomes have been reported in trials which employed a vitamin C intervention strategy. These include faster organ function recovery, lower inflammatory response, reduced length of stay in the ICU, reduced length of stay in hospital, reduced mortality rate, increased ventilator-free days and reduced incidence of post-operative atrial fibrillation , , , , , , , , , , , , , , , , , , , , .
Although the current literature is yet to provide robust evidence on the benefits of high-dose vitamin C intervention in the critically ill, there is already an indication that only high doses are capable of correcting low plasma vitamin C levels , , . The analysis of vitamin C in these patients is therefore imperative to monitor levels upon admission and during high-dose intervention to ensure that the dose and duration of the therapy is sufficient to maintain targeted blood levels of vitamin C . It should be noted that vitamin C is suggested to have a pro-oxidant effect in the presence of freely dissolved metals, such as excess iron in haemodialysis patients . However, more conclusive work in this area is required .
Any testing procedure of vitamin C that is used to monitor current plasma levels, provides information on the pharmacokinetics of therapy or is used to calculate optimal dosages requires a protocol. This will reduce sample loss or degradation prior to analysis. It must also include a reliable, robust method of measurement, which covers the entire investigatory range of deficiency, hypovitaminosis C and high-dose supranormal levels.
Vitamin C has several measurands that can be analysed separately or in combination:
ascorbic acid only;
ascorbic acid and its oxidised form dehydroascorbic acid (DHA) separately;
total vitamin C (the sum of ascorbic acid + DHA) where DHA is reduced back to ascorbic acid prior to analysis.
Either methods B or C provides an overview of the total antioxidant availability. Measuring only ascorbic acid underestimates this by excluding DHA which has approximately the same biologically activity as ascorbic acid . The term vitamin C will be used as a general term from this point on and will encompass all forms of vitamin C unless otherwise noted.
Pre-analytical variables principally stem from the patient’s status, sample integrity (i.e. haemolysis) or sample handling and processing (i.e. type of anticoagulant, photosensitivity, temperature, pH and storage) and are likely to affect the accuracy of the measurements. Intra-individual variables such as the fasting state, smoking status, iron supplement intake or medications may affect the vitamin C status and are something to be aware of. However, in an ICU environment these become less pertinent, but this information should still be collected by the admissions team. In vitro haemolysis is another pre-analytical error which may occur despite careful attention to the necessary collection requirements. Haemolysis causes the release of free haemoglobin-iron which can rapidly reduce vitamin C. The effect can be minimised by the addition of tris(2-carboxyethyl)phosphine hydrochloride (TCEP), to the stabilised plasma. However, the dilution of the plasma with the reducing reagent must be corrected for before result reporting.
The analysis of vitamin C was included in the study design of several trials , , , , , . However, details regarding sample handling and processing are typically lacking. Of the six trials which included vitamin C analysis the majority opted for plasma (67%) as the sample type whilst the remainder used serum (33%). Sample handling included cold centrifugation (33%) and storage was always frozen (50%) where mentioned. The addition of a stabiliser and/or reducing reagent was disclosed in some (50%) (Supplementary Material 2).
Plasma is the most common matrix used for vitamin C analysis. However, tissue levels of vitamin C can be up to 100-fold more concentrated , , . Plasma vitamin C concentrations rise and fall rapidly during supplementation/depletion unlike leukocytes, where changes in concentration levels are less dramatic , . Therefore, plasma vitamin C may reflect rapid changes in the metabolic demands of the body whilst levels in leukocytes may be a better reflection of body stores , . As vitamin C deficiency is largely unseen in the general population, the need to obtain information on tissue concentrations has never been of relevance. This is highlighted in only a handful of publications which have determined the tissue concentration of vitamin C in monocytes, neutrophils, lymphocytes, platelets, erythrocytes, skeletal muscle and several organ types , , , , , . Supplementation with vitamin C does appear to increase tissue levels; however, there is currently no solid evidence to suggest whether there is a correlation between tissue and plasma vitamin C levels , , , , .
The most convenient way to measure tissue vitamin C levels would be through leukocytes. However, leukocyte vitamin C analysis requires a relatively large sample volume and is often plagued with poor precision and accuracy through contamination (e.g. platelets) during the matrix separation , , . Additionally, there is little information on expected values of the body stores of vitamin C in healthy and diseased populations.
Plasma analysis of vitamin C is a faster and simpler method and can be readily separated from other contaminating sources. Commercial kits, quality controls and calibrators are available as are plasma vitamin C external quality assurance (EQA) programs streamlining method adoption and validation. This simplicity has driven plasma vitamin C analysis over tissue matrices.
The choice of vacutainer was investigated by Lykksefeldt who concluded that K3-ethylenediaminetetraacetic acid (EDTA) tubes were superior in preventing ex vivo metabolism of vitamin C to DHA . However, K2-EDTA, lithium heparin and plain serum tubes were also found to be excellent for total vitamin C analysis, where the DHA is reduced back to ascorbic acid prior to measurement. DHA can be reduced to ascorbic acid through either the addition of a reducing reagent or by shifting the pH of the solution so that it is lower than the pKa of vitamin C (4.7) as the reaction between ascorbic acid and DHA is reversible (Figure 2) . This has been backed by other studies which have successfully used either EDTA or lithium heparin in their stability studies , , , .
Vitamin C is notoriously unstable with significant ex vivo metabolism to DHA and 2,3-diketogluonic acid within 2 h of sample collection (Figure 2) , . Separation of the serum or plasma should occur immediately followed by storage in an ultra-low-temperature environment (−70 and −80 °C). Investigations into delayed separation indicated significant loss after 2–6 h post collection in untreated samples kept at 4 °C or up to 16 h with the inclusion of diothreitol (DTT) , , . Untreated samples, kept at room temperature, had a greatly reduced stability and vitamin C could not be recovered following the addition of a reducing reagent .
Lyophilised vitamin C material, preserved with the reducing reagent DTT, has been shown to be stable for up to 6 years . A second reducing reagent, TCEP, has also been used with success to achieve stability of to up to 1 year when reduction is performed prior to analysis , . Other studies incorporated an acid for sample deproteinisation, such as trichloroacetic acid (TCA), metaphosphoric acid (MPA) or perchloric acid (PCA) as well as a metal chelator such as EDTA or diethylene-triaminepentaacetic acid (DTPA) instead of a reducing reagent to stabilise the sample , , , , . These have also had success with recorded stability of up to 1.5 years.
Ultra-low temperatures between −70 and −80 °C for long-term storage have been investigated with stability duration from 80 days to 5 years for samples that have been treated with a stabilising reagent , . Non-stabilised plasma samples at these temperatures have a reduced shelf life of 2–52 weeks , . Those stored at −20 °C or 4 °C, or room temperature were only deemed suitable for short-term storage −71).
Salminen and colleagues investigated the stability of vitamin C post sample preparation to mimic unforeseen delays of analysis . A loss of <5% was determined in samples kept at 4 °C for up to 48 h. Additionally, if samples were frozen post sample preparation and re-analysed, losses >20% were observed. Each of the processes described above have had varying success in extending the stability and reducing the pre-analytical variables of vitamin C. Currently, the only universal agreement is that EDTA and lithium heparin tubes are an appropriate collection tube and that separation of the serum or plasma should be performed immediately after collection. The addition of a stabiliser or reducing reagent and storage conditions vary among these studies. Despite there being no collective agreement on a single acid or metal chelator, the inclusion of a stabilising reagent during sample processing is an appropriate procedure to accommodate sample instability and reduce pre-analytical errors.
The imprecision and bias of a methodology can be one of the greatest contributors to the generation of erroneous results. The analytical performance of vitamin C measurement methodologies had been previously explored by Margolis and colleagues back in 1993−1994 and 2003 , . The comparisons performed from 1993 to 1994 were designed by the National Institute of Standards and Technology (NIST). Four serum sample lots containing varying vitamin C concentrations were preserved in MPA and sent out to participating laboratories to be analysed in duplicate. These distributions occurred three times and were titled “Round robin IV, V and VI”.
Over the study period, 23 laboratories participated in this exercise, which included several methodologies. These were auto-analyser (n=1), dichloro-phenolindophenol (DCIP, n=2), o-phenylenediamine (OPD, n=1), dinitrophenylhydrazine (DNPH, n=3), enzymatic (n=1), liquid chromatography (LC)-OPD detection (n=1), LC-electrochemical detection (LC-ECD, n=14) and LC with spectrophotometric detection (n=1). This trial concluded that the measurement of ascorbic acid had a much higher repeatability estimate compared to that of total vitamin C.
The repeatability estimate was based on the within-sample and within-lot data from each participant. Additional findings from this study included the overestimation of total vitamin C in DNPH methodologies and the underestimation in the OPD method. These comparison studies resulted in poor interlaboratory agreement with an average coefficient of variance (CV) of 15.0% (min 12.0%, median 15.5%, max 17.0%). This was calculated from all four lots after the removal of the DNPH and OPD methods from the data. It was concluded that total vitamin C results cannot be compared among different methods in the absence of reference materials .
In 2003, Margolis and colleagues distributed samples with two levels of a certified reference material for vitamin C, developed by NIST, in a serum matrix stabilised in MPA to 17 laboratories , . A CV of 21.9% for low vitamin C concentration (10.07±0.21 μmol/L) and 19.2% (30.57±0.28 μmol/L) for high vitamin C concentration was observed indicating a lack of interlaboratory accuracy. There were several methodologies used in this study, which mainly included high performance liquid chromatography (HPLC) with differing detection methods. An overview of the methods and their accompanying performance can be seen in Table 1.
|Methodology||No. of labs||Low vitamin C level||High vitamin C level|
|Average, μmol/L||CV%||Average, μmol/L||CV%|
Targets set by NIST: low vitamin C level 10.07 μmol/L, high vitamin C level 30.57 μmol/L. ECD, electrochemical detection; UV, ultraviolet. aCV% was calculated only if the participation was ≥2.
The six trials which included vitamin C analysis typically employed HPLC with various detection systems (83%) except one which employed an enzymatic methodology (17%). The measurand is total vitamin C for some (50%) and for the others it was unclear (50%). The lower limits of the reference indices varied from 20 to 50 μmol/L and the upper limits from 50 to 125 μmol/L. No trial indicated the assay imprecision or any enrolment in an EQA program (Supplementary Material 2).
The literature search produced only one publication which directly compared two methods (HPLC with ECD and HPLC with ultraviolet [UV] detection), for total vitamin C quantification . Regression and Bland-Altman analysis were performed on a total of 80 samples. The results between the two methods were determined to be equivalent for total vitamin C. Over the range measured (4–133 μmol/L) a small bias (3.7 μmol/L) was observed for the HPLC-UV method, which did not exist at concentrations of clinical interest, <28.4 μmol/L. It is unclear whether this bias would increase at levels >133 μmol/L as these concentrations are likely to be observed in high-dose vitamin C trials , , .
For the outcomes of any trials to be comparable, the analytical techniques utilised must be traceable to a higher-order methodology or directly compared against known target values, typically through an EQA program. There is currently no higher-order reference method or procedure for vitamin C listed in the Joint Committee of Traceability in Laboratory Medicine (JCTLM) database . Therefore, results generated from different studies can only be compared if their analytical methods participate in an EQA program and the reported results are equivalent.
Previous studies by Margolis and colleagues highlighted the need for improvement in vitamin C analysis , . Since then, there has been the development of several EQA programs for serum and plasma vitamin C based in the US (NIST ceased the program in 2015), Germany (INSTAND e.V.) and Australasia (RCPAQAP).
The INSTAND e.V. program has over 30 years of experience in a plasma vitamin C EQA program, with the majority of the participants employing HPLC-based analytical methodologies . The earliest data available online indicates that, in October 2014, this program had 45 participants (average 47.7, median 46.5, maximum 63 in 2018 and minimum 30 in 2015) giving it the largest number of participants for a plasma vitamin C EQA program. The program has four rounds each year with each round consisting of two lyophilised samples with a total of eight samples analysed annually.
Based on the available online data, target values are set by INSTAND e.V. to cover an approximate plasma vitamin C range of 30–163 μmol/L in which the program does not appear to utilise the same concentration sample twice . This EQA program includes a generous ±36% allowable error over the entire concentration range. Since 2014, this program has achieved an average CV of 11.8% for each round (median 11.5%, low 8.8% and high 17.1%).
The RCPAQAP plasma vitamin C program was initiated in 2010 where 13 laboratories participated in the RCAPQAP’s cycle 22, which included 12 lyophilised samples (six linearly related samples analysed in duplicate) over a 6-month period . The allowable error for this program is based on biological variation data with a ±25% for concentrations >36 μmol/L and ±9.0 μmol/L for concentrations up to 36 μmol/L. According to the RCPAQAP’s end of cycle 22 report, there were three analytical methods employed; HPLC –fluorescence (n=9), colourmetric analysis (n=2), 2,4 dinitrophenylhydrazine analysis (n=1) . One laboratory did not disclose the analytical principle. Overall, these laboratories produced an average CV of 18.9% (median 13.3%). This correlates with the two previous trials by Margolis and colleagues with calculated CVs of 15–21.9%.
In one of the recent end of cycle reports (cycle 39) there were 22 participants and four reported analytical methods; HPLC- fluorescence (n=7), HPLC-ECD (n=3), HPLC- UV (n=9) and enzymatic endpoint (n=2) with at least seven countries participating , . Again, one laboratory did not disclose the analytical principle. This cycle showed a significant improvement from the original cycle with an overall average CV of 5.9% (median 6.9%). In fact, based on the average CV% from the end of cycle reports over the last decade, the vitamin C program is one of the most improved programs in the RCPAQAP’s repertoire .
Overall, the statistics from both quality assurance programs indicate good interlaboratory agreement and imply that current analytical methodologies for vitamin C analysis provide harmonised results. These improvements in interlaboratory agreement may stem from a shift away from enzymatic, spectrophotometric and colorimetric procedures, which were prone to low sensitivity and specificity as well as interferences, towards HPLC-based methodologies . Additionally, these often utilise commercially manufactured kits which include stabilising reagents and internal standards, further improving method standardisation . Finally, the development of EQA programs has clearly aided in the improvement of interlaboratory agreement of vitamin C.
The origins of the clinical decision point for vitamin C deficiency appear to be founded from early works on depletion/repletion studies , , . Very early studies suggested levels below 23 and 28 μmol/L were indicative of vitamin C depletion . In 1973, the Nutrition Canada national survey recommended levels of 11.4–22.8 μmol/L as indicative of a low vitamin C range . This was re-enforced by the findings in the second National Health and Nutrition Examination Survey in the US (1976–1980) .
Currently there does not appear to be standardised normal, or expected, reference indices for serum/plasma vitamin C. Many of the published indices range from 23 to 100 μmol/L , , , , . One epidemiological study on European populations reported a vitamin C reference range of 6.25–116.81 μmol/L across five countries . However, there does appear to be some agreement at the diagnostic threshold of >23 μmol/L being considered sufficient. Therefore, vitamin C should be reported using the diagnostic threshold value. A list of all the recommendations across the total testing process and their rationale can be seen in Table 2.
|Pre-analytical||1. Tube type: Samples should be collected into lithium heparin or EDTA tubes||Minimal sample oxidation has been observed in these tube types compared to others , , , |
|2. Sample handling: Samples should be centrifuged at 4 °C after collection and the plasma should be separated immediately||Significant analyte loss has been associated with delayed sample separation , , |
|3. Stabilisation: An acid stabiliser with a metal chelator (e.g. PCA/DTPA) should be added in equal volumes to the separated plasma||Stability of samples recorded up to 1.5 years , , , , |
|4. Storage: Separated, stabilised plasma samples should be stored between −70 and −80 °C||Higher temperatures suitable for only very short-term stability ], , , |
|Analytical||5. Quantification: Plasma samples should be analysed using HPLC-based methodologies (e.g. ECD, UV or mass spectrometry)||Colorimetric, spectrophotometric and enzymatic methods are prone to low sensitivity and specificity and have known biological interferences |
|6. Quality assurance: The plasma vitamin C method must be enrolled in an EQA program||External unbiased monitoring of the performance of the methodology|
|7. Delayed analysis: Once prepared, samples must be run within 48 h. Samples should not be frozen after preparation||Loss of analyte up to 5% when analysed at 48 h. Loss if >20% when prepared samples are frozen before analysis |
|Post-analytical||8. Reference indices
Deficiency: <11 μmol/L
Hypovitaminosis C: 11–23 μmol/L
Replete/sufficient: >23 μmol/L
|These have large-scale national surveys which agreed upon these indices , |
The efficacy of high-dose vitamin C therapy is still in question due to many of the published trials being single centre, unblinded, small in size, inclusive of post-hoc/retrospective analysis or affected by additional confounders. To determine whether high-dose vitamin C supplementation is clinically beneficial to ICU patients, more vigorous, well-planned and high-quality RCTs are still required and with them the need for a robust analytical method to help define the physiological role vitamin C plays in the critically ill.
The INSTAND e.V. and RCPAQAP EQA programs have indicated that the current methodologies for vitamin C analysis are fit for purpose and there is acceptable interlaboratory agreement. However, both NIST and RCPAQAP integrate a stabiliser or reducing reagent into the medium of their EQA samples to stop the oxidation of vitamin C , . In patient samples, there are often no stabilisers and oxidation will readily occur ex vivo and continue to do so up until analysis. Therefore, several factors need to be considered before implementing a vitamin C method for routine analysis or incorporation into a high-dose vitamin C RCT.
How should the samples be collected and stored?
Laboratories must consider that pre-analytical error cannot be monitored through EQA programs. Therefore, incorporating appropriate sample handling and processing techniques into a method protocol is essential to reduce any loss before analysis minimising pre-analytical error. This includes following the recommendations set out in Table 2.
Is the method HPLC based?
HPLC methodologies for vitamin C quantification have become increasingly popular over the years. Analysis by HPLC has increased by 53% since the inception of the RCPAQAP plasma vitamin C program in 2010 and now accounts for >90% of the participants. These methods are reliable and robust with some instrument formats accommodating commercially available reagent kits. These kits may include calibrators, mobile phase, light-protective centrifuge tubes, precipitation reagents and an internal standard. One commercially available kit was employed by 33% of the participants enrolled in the RCPAQAP cycle 39 for plasma vitamin C which achieved a CV of 6.4%. HPLC-ECD is considered the unofficial gold standard method for vitamin C quantification but HPLC-UV has been shown to perform equivalently , .
Does the method cover the expected range of deficiency and supranormal levels?
HPLC-based methods are highly sensitive with a large dynamic range with published vitamin C methods reporting limit of quantitation levels of 1.0–5.6 μmol/L and linearity up to 5000 μmol/L , . These ranges cover both vitamin C deficiency, <11.0 μmol/L, and high, >250 μmol/L, levels.
What should be reported (ascorbic acid, ascorbic acid and DHA or total vitamin C)?
Measuring only ascorbic acid may result in the underestimation of bioavailability as it is likely that some of the supplemented vitamin C has been metabolised to DHA, which has approximately the same biological activity as ascorbic acid . DHA is commonly calculated by subtracting the ascorbic acid result from the total vitamin C result, which requires the addition of a strong acid or reducing reagent and a second analysis . However, it can be simultaneously quantified with ascorbic acid . Measuring total vitamin C is a simpler method for monitoring patient vitamin C concentrations in the ICU. As the concentration of DHA is not pertinent and vitamin C is being supplemented intravenously, it would appear more beneficial to monitor the total vitamin C availability to ensure its blood levels remain high.
The current analytical performance of vitamin C methodologies are acceptable for the requirements of high-dose vitamin C RCTs. However, for vitamin C to be correctly integrated into an interventional therapy with a robust reliable analytical methodology several factors are required. These include the establishment of proper sample handling and processing protocols including the addition of a stabiliser and ultra-low-temperature storage, the incorporation of HPLC-based methodology and the enrolment and participation in an EQA program for vitamin C. The harmonisation of these processes and protocols will also aid in ensuring that there is agreement in results between laboratories. Adherence to these recommendations for the procedures of collection, storage, analysis and interpretation of vitamin C in the clinical setting will support the outcomes of future clinical trial data.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
1. De Tullio MC. Beyond the antioxidant: the double life of vitamin C. In: Stranger O, editor. Water Soluble Vitamins Subcellular Biochemistry. 56. Dordrecht: Springer; 2012. p. 46–65. Search in Google Scholar
2. Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, vitamin C and thiamine for the treatment of severe sepsis and septic shock: a retrospective before-after study. Chest 2017;151:1229–38. Search in Google Scholar
3. Beale RJ, Sherry T, Lei K, Campbell-Stephen L, McCook J, Smith J, et al. Early enteral supplementation with key pharmaconutrients improves Sequential Organ Failure Assessment score in critically ill patients with sepsis: Outcome of a randomized, controlled, double-blind trial. Crit Care Med 2008;36:131–44. Search in Google Scholar
4. Berger MM, Soguel L, Shenkin A, Revelly J, Pinget C, Baines M, et al. Influence of early antioxidant supplements on clinical evolution and organ function in critically ill cardiac surgery, major trauma, and subarachnoid hemorrhage patients. Crit Care 2008;12:R101. Search in Google Scholar
5. Luo M, Fernandez-Estivariz C, Jones DP, Accardi CR, Alteheld B, Bazargan N, et al. Depletion of plasma antioxidants in surgical intensive care unit patients requiring parenteral feeding: Effects of parenteral nutrition with or without alanyl-glutamine dipeptide supplementation. Nutrition 2008;24:37–44. Search in Google Scholar
6. Colby JA, Chen WT, Baker WL, Coleman CI, Reinhart K, Kluger J, et al. Effect of ascorbic acid on inflammatory markers after cardiothoracic surgery. Am J Health Syst Pharm 2011;68:1632–9. Search in Google Scholar
7. Castillo R, Rodrigo R, Perez F, Cereceda M, Asenjo R, Zamorano J, et al. Antioxidant therapy reduces oxidative and inflammatory tissue damage in patients subjected to cardiac surgery with extracorporeal circulation. Basic Clin Pharmacol Toxicol 2011;108:256–62. Search in Google Scholar
8. Papoulidis P, Ananiadou O, Chalvatzoulis E, Ampatzidou F, Koutsogiannidis C, Karaiskos T, et al. The role of ascorbic acid in the prevention of atrial fibrillation after elective on-pump myocardial revascularization surgery: a single-center experience – A pilot study. Interact Cardiovasc Thorac Surg 2011;12:121–4. Search in Google Scholar
9. Baradari AG, Zeydi AE, Espahbodi F, Aarabi M. The effect of intravenous vitamin C on the phosphorus level reduction in hemodialysis patients: a double blind randomized clinical trial. Med Glas (Zenica) 2012;9:37–41. Search in Google Scholar
10. Bjordahl PM, Helmer SD, Gosnell DJ, Wemmer GE, O’Hara WW, Milfeld DJ. Perioperative supplementation with ascorbic acid does not prevent atrial fibrillation in coronary artery bypass graft patients. Am J Surg 2012;204:862–7. Search in Google Scholar
11. Heyland D, Muscedere J, Wischmeyer PE, Cook D, Jones G, Albert M, et al. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med 2013;368:1489–97. Search in Google Scholar
12. Nogueira CR, Borges F, Lameu E, Franca C, Ramalho A. Effects of supplementation of antioxidant vitamins and lipid peroxidation in critically ill patients. Nutr Hosp 2013;28:1666–72. Search in Google Scholar
13. Dehghani MR, Majidi N, Rahmani A, Asgari B, Rezaei Y. Effect of oral vitamin C on atrial fibrillation development after isolated coronary artery bypass grafting surgery: a prospective randomized clinical trial. Cardiol J 2014;21:492–9. Search in Google Scholar
14. Fowler AA, Syed AA, Knowlson S, Sculthorpe R, Farthing D, DeWilde C, et al. Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis. J Transl Med 2014;12:1–10. Search in Google Scholar
15. Van Zanten ARH, Sztark FS, Kaisers UD, Zielmann S, Felbinger TW, Sablotzk AR, et al. High-protein enteral nutrition enriched with immune-modulating nutrients vs standard high-protein enteral nutrition and nosocomial infections in the ICU: a randomized clinical trial. J Am Med Assoc 2014;312:514–24. Search in Google Scholar
16. Sarzaeem M, Shayan N. Vitamin C in prevention of atrial fibrillation after coronary artery bypass graft: double-blind randomized clinical trial. Tehran Univ Med J 2014;71:787–93. Search in Google Scholar
17. Sadeghpour A, Alizadehasl A, Kyavar M, Sadeghi T, Moludi J, Gholizadeh F, et al. Impact of vitamin C supplementation on post-cardiac surgery ICU and hospital length of stay. Anesth Pain Med 2015;5:e25337. Search in Google Scholar
18. Samadikhah J, Golzari SE, Sabermarouf B, Karimzadeh I, Tizro P, Khanli HM, et al. Efficacy of combination therapy of statin and vitamin C in comparison with statin in the prevention of post-CABG atrial fibrillation. Adv Pharm Bull 2014;4:97–100. Search in Google Scholar
19. Duffy MJ, O’Kane CM, Stevenson M, Young IS, Harkin DW, Mullan BA, et al. A randomized clinical trial of ascorbic acid in open abdominal aortic aneurysm repair. Intensive Care Med Exp 2015;3:1–15. Search in Google Scholar
20. Howe KP, Clochesy JM, Goldstein LS, Owen H. Mechanical ventilation antioxidant trial. Am J Crit Care 2015;24:440–5. Search in Google Scholar
21. Das D, Sen C, Goswami A. Effect of vitamin C on adrenal suppression by etomidate induction in patients undergoing cardiac surgery: a randomized controlled trial. Ann Card Anaesth 2016;19:410–7. Search in Google Scholar
22. Zabet MH, Mohammadi M, Ramezani M, Khalili H. Effect of high-dose ascorbic acid on vasopressor’s requirement in septic shock. J Res Pharm Pract 2016;2:94–100. Search in Google Scholar
23. Antonic M, Lipovec R, Gregorcic F, Juric P, Kosir G. Perioperative ascorbic acid supplementation does not reduce the incidence of postoperative atrial fibrillation in on-pump coronary artery bypass graft patients. J Cardiol 2017;69:90–102. Search in Google Scholar
24. Alshafey MK, Elrakhawy HM, Rezk ME, Moustafa HM. Role of ascorbic acid in reduction of the incidence of the atrial fibrillation in patients under B-blocker and undergoing coronary artery bypass graft operation in early post-operative period. J Egypt Soc Cardiothorac Surg 2017;25:198–203. Search in Google Scholar
25. Palli E, Makris D, Papanikolaou J, Garoufalis G, Tsilioni I, Zygoulis P, et al. The impact of N-acetylcysteine and ascorbic acid in contrast-induced nephropathy in critical care patients: an open-label randomized controlled study. Crit Care 2017;21:1–9. Search in Google Scholar
26. Rebrova TY, Shipulin VM, Afanasiev SA, Vorobieva EV, Kiyko OG. Experience with administration of ascorbic acid as antioxidant after coronary artery bypass surgery with cardiopulmonary bypass. Kardiologiia 2012;52:73–6. Search in Google Scholar
27. Ebade A, Taha WS, Saleh RH, Fawzy A. Ascorbic acid versus magnesium for the prevention of atrial fibrillation after coronary artery bypass grafting surgery. Egypt J Cardiothorac Anesth 2014;8:59–65. Search in Google Scholar
28. Giladi AM, Dossett LA, Fleming SB, Abumran NN, Cotton BA. High-dose antioxidant administration is associated with a reduction in postinjury complications in critically ill trauma patients. Injury 2011;42:78–82. Search in Google Scholar
29. Kim W, Jo E, Eom JS, Mok J, Kim M, Kim KU, et al. Combined vitamin C, hydrocortisone, and thiamine therapy for patients with severe pneumonia who were admitted to the intensive care unit: propensity score-based analysis of a before-after cohort study. J Crit Care 2018;47:211–8. Search in Google Scholar
30. Collier BR, Giladi AM, Dossett LA, Dyer L, Fleming SB, Cotton BA. Impact of high-dose antioxidants on outcomes in acutely injured patients. J Parenter Enteral Nutr 2008;32:384–8. Search in Google Scholar
31. Carr AC, Maggini S. Vitamin C and immune function. Nutrients 2017;9:1211. Search in Google Scholar
32. Oudemans-van Straaten HM, Spoelstra-de Man AM, de Waard MC. Vitamin C revisited. Crit Care 2014;18:1–13. Search in Google Scholar
33. Padayatty SJ, Levine M. Vitamin C: the known and the unknown and Goldilocks. Oral Dis 2016;22:463–93. Search in Google Scholar
34. Marik PE. Hydrocortisone, ascorbic acid and thiamine (HAT therapy) for the treatment of sepsis. Focus on ascorbic acid. Nutrients 2018;10:1762. Search in Google Scholar
35. Rumsey SC, Levine M. Absorpition, transport and disposition of ascorbic acid in humans. J Nutr Biochem 1998;9:116–30. Search in Google Scholar
36. Mangels AR, Block G, Frey CM, Patterson BH, Taylor P, Norkus EP, et al. The bioavailability to humans of ascorbic acid from oranges, orange juice and cooked broccoli is similar to that of synthetic ascorbic acid. J Nutr 1993;123:1054–61. Search in Google Scholar
37. Jacob RA, Omaye ST, Skala JH, Leggott PJ, Rothman DL, Murray PA. Experimental vitamin C depletion and supplementation in young men. Nutrient interactions and dental health effects. Ann N Y Acad Sci 1987;498:333–46. Search in Google Scholar
38. Jacob RA, Pianalto FS, Agee RE. Cellular ascorbate depletion in healthy men. J Nutr 1992;122:1111–8. Search in Google Scholar
39. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. PNAS 1996;93:3704–9. Search in Google Scholar
40. Marik PE. Vitamin C for the treatment of sepsis: the scientific rationale. Pharmacol Ther 2018;189:63–70. Search in Google Scholar
41. Padayatty SJ, Katz A, Wang Y, Eck P, Kwon O, Lee J. Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr 2002;22:18–35. Search in Google Scholar
42. Berger MM, Oudemans-van Straaten HM. Vitamin C supplementation in the critically ill patient. Curr Opin Clin Nutr Metab Care 2015;18:193–201. Search in Google Scholar
43. Spoelstra-de Man AM, Elbers PW, Oudemans-van Straaten HM. Vitamin C: should we supplement? Curr Opin Crit Care 2018;24:248–55. Search in Google Scholar
44. Long CL, Maull KI, Krishnan RS, laws MD, Geiger JW, Borghesi L, et al. Ascorbic acid dynamics in the seriously ill and injured. J Surg Res 2003;109:144–8. Search in Google Scholar
45. Carr AC, Frei B. Towards a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am J Clin Nutr 1999;69:1089–107. Search in Google Scholar
46. Carr AC, Rosengrave PC, Bayer S, Chambers S, Mehrtens J, Shaw GM. Hypovitaminosis C and vitamin C deficiency in critically ill patients despite recommended enteral and parenteral intakes. Crit Care 2017;21:1–10. Search in Google Scholar
47. Spoelstra-de Man AM, Elbers PW, Oudemans-van Straaten HM. Making sense of early high-dose intravenous vitamin C in ischemia/reperfusion injury. Crit Care 2018;22:1–9. Search in Google Scholar
48. Langlois M, Duprez D, Delanghe J, De Buyzere M, Clement DL. Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis. Circulation 2001;103:1863–8. Search in Google Scholar
49. Wilson JX. Evaluation of vitamin C for adjuvant sepsis therapy. Antioxid Redox Signal 2013;19:2129–40. Search in Google Scholar
50. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of cardiovascular disease in men: The Physicians’ Health Study II Randomized Controlled Trial. J Am Med Assoc 2008;300:2123–33. Search in Google Scholar
51. De Grooth HJ, Spoelstra-de Man AM, Oudemans-van Straaten HM. Early plasma vitamin C concentration, organ dysfunction and ICU mortality. Int Care Med 2014;40:S199–200. Search in Google Scholar
52. Hudson EP, Collie JT, Fuji T, Luethi N, Udy AA, Doherty S, et al. Pharmacokinetic data support 6-hourly dosing of intravenous vitamin C to critically ill patients with septic shock. Crit Care Resusc 2019;21:236–42. Search in Google Scholar
53. De Vriese AS, Borrey D, Mahieu E, Claeys I, Stevens L, Vanhaeverbeke A, et al. Oral vitamin C administration increases lipid peroxidation in hemodialysis patients. Nephron Clin Pract 2008;108:c28–34. Search in Google Scholar
54. Carr AC, Frei B. Does vitamin C act as a pro-oxidant under physiological conditions? FASEB J 1999;13:1007–24. Search in Google Scholar
55. Blanchard J, Conrad KA, Watson RR, Garry PJ, Crawley JD. Comparison of plasma, mononuclear and polymorphonuclear leucocyte vitamin c levels in young and elderly women during depletion and supplimentation. Eur J Clin Nutr 1989;43:97–106. Search in Google Scholar
56. Omaye ST, Schaus EE, Kutnink MA, Hawkes WV. Measurement of vitamin c in blood components by high-performance liquid chromatography. Implication in assessing vitamin c status. Ann N Y Acad Sci 1987;498:389–401. Search in Google Scholar
57. Gibson RS. Principles of nutritional assessment. 2nd ed. Oxford: Oxford University Press; 2005. Search in Google Scholar
58. Lee W, Hamernyik P, Hutchinson M, Raisys VA, Labbe RF. Ascorbic acid in lymphocytes: cell preparation and liquid-chromatographic assay. Clin Chem 1982;28:2165–9. Search in Google Scholar
59. Carr AC, Bozonet SM, Pullar JM, Simcock JW, Vissers MC. Human skeletal muscle ascorbate is highly responsive to changes in vitamin C intake and plasma concentrations. Am J Clin Nutr 2013;97:800–7. Search in Google Scholar
60. Levine M, Wang Y, Padayatty SJ, Morrow J. A new recommended dietary allowance of vitamin C for healthy young women. PNAS 2001;98:9842–6. Search in Google Scholar
61. Jacob RA, Skala JH, Omaye ST. Biochemical indices of human vitamin C status. Am J Clin Nutr 1987;46:818–26. Search in Google Scholar
62. Bates CJ, Rutishauser IH, Black AE, Paul AA. Long-term vitamin status and dietary intake of healthy elderly subjects. Br J Nutr 1977;42:43–56. Search in Google Scholar
63. Evans RM, Currie L, Campbell A. The distribution of ascorbic acid between various cellular components of blood, in normal individuals, and its relation to the plasma concentration. Br J Nutr 1982;47:473–82. Search in Google Scholar
64. Sauberlich HE, Dowdy RP, Skala JH. Laboratory tests for the assessment of nutritional status. Florida: CRC Press Inc.; 1974. Search in Google Scholar
65. Lykkesfeldt J. Ascorbate and dehydroascorbic acid as biomarkers of oxidative stress: validity of clinical data depends on vacutainer system used. Nutr Res 2012;32:66–9. Search in Google Scholar
66. U.S. National Library of Medicine. PubChem [https://pubchem.ncbi.nlm.nih.gov/compound/54670067] Accessed: 20 Aug 2019. Search in Google Scholar
67. Salminen I, Alfthan G. Plasma ascorbic acid preparation and storage for epidemiological studies using TCA precipitation. Clin Biochem 2008;41:723–7. Search in Google Scholar
68. Ching SY, Prins AW, Beilby JP. Stability of ascorbic acid in serum and plasma prior to analysis. Ann Clin Biochem 2002;39:518–20. Search in Google Scholar
69. Karlsen A, Blomhoff R, Gundersen TE. Stability of whole blood and plasma ascorbic acid. Eur J Clin Nutr 2007;61:1233–6. Search in Google Scholar
70. Pullar JM, Bayer S, Carr AC. Appropriate handling, processing and analysis of blood samples is essential to avoid oxidation of vitamin C to dehydroascorbic acid in clinical samples. Antioxidants 2018;7. Search in Google Scholar
71. Lee SA, Tsai S, Lin S, Chen B, Tsai L. Stability of total ascorbic acid in DTT-preserved plasma stored at 4 °C. J Food Drug Anal 2004;12:217–20. Search in Google Scholar
72. Margolis SA, Duewer DL. Measurement of ascorbic acid in human plasma and serum: stability, intralaboratory repeatability, and interlaboratory reproducibility. Clin Chem 1996;42:1257–62. Search in Google Scholar
73. Baierle M, de Bairros A, Moreira AP, Bulcão M, Roehrs M, de Freitas F, et al. Serum quantification of vitamin C by HPLC-UV and stability study. Quim Nova 2012;35:403–7. Search in Google Scholar
74. Lykkesfeldt J. Ascorbate and dehydroascorbic acid as reliable biomarkers of oxidative stress: analytical reproducibility and long-term stability of plasma samples subjected to acidic deproteinization. Cancer Epidemiol Biomarkers Prev 2007;16:2513–6. Search in Google Scholar
75. Margolis SA, Vangel M, Duewer DL. Certification of standard reference material 970, ascorbic acid in serum, and analysis of associated interlaboratory bias in the measurement process. Clin Chem 2003;49:463–9. Search in Google Scholar
77. Robitalle L, Hoffer LJ. A simple method for plasma total vitamin C analysis suitable for routine clinical laboratory use. Nutr J 2016;15:1–9. Search in Google Scholar
78. de Grooth H, Manubulu-Choo W, Zandvliet AS, Spoelstra-de Man AM, Girbes AR, Swart EL, et al. Vitamin C pharmacokinetics in critically ill patients: a randomized trial of four IV regimens. Chest 2018;153:1368–77. Search in Google Scholar
79. INSTAND e.V. Plasma Vitamin C external quality assurance program. Nathalie Wojtalewicz; 2019. Search in Google Scholar
80. INSTAND e.V. EQAS Online 2019 [Available from: https://www.instand-ev.de/no_cache/en/eqas-online/service-for-eqa-tests/. Search in Google Scholar
82. RCPA Quality Assurance Programs. Plasma vitamin C external quality assurance program. Samantha Liu; 2019. Search in Google Scholar
84. James B, Graham P. Participation in RCPAQAP external quality assurance correlates with improved laboratory results. In: 5th International Vitamin Conference, Sydney, Australia; 2018. Search in Google Scholar
85. Hodges RE, Hood J, Canham JE, Sauberlich HE, Baker EM. Clinical manifestations of ascorbic acid deficiency in man. Am J Clin Nutr 1971;24:432–43. Search in Google Scholar
86. Cradon JH, Lund CC. Vitamin C deficiency in an otherwise normal adult. N Engl J Med 1940;222:748–52. Search in Google Scholar
87. Sauberlich HE. Vitamin C status: Methods and findings. Ann N Y Acad Sci 1975;258:438–50. Search in Google Scholar
88. Chromsystems. Instruction manual for the HPLC analysis of vitamin C in plasma/serum. 2015:1–18. Search in Google Scholar
89. Olmedilla B, Granado F, Southon S, Wright AJA, Blanco I, Gil-Martinez E, et al. Serum concentrations of carotenoids and vitamins A, E, and C in control subjects from five European countries. Br J Nutr. 2007;85:227–38. Search in Google Scholar
90. RCPAQAP. Vitamins Advisory Committee meeting. Alexandria, NSW, 2019. Search in Google Scholar
91. Clark ZD, Frank EL. Development and implementation of an HPLC-ECD method for analysis of vitamin C in plasma using single column and automatic alternating dual column regeneration. Pract Lab Med 2016;6:25–37. Search in Google Scholar
92. Kim Y, Kim M. HPLC-UV method for the simultaneous determinations of ascorbic acid and dehydroascorbic acid in human plasma. Trans Clin Pharmacol 2016;24:37–42. Search in Google Scholar
93. Kim Y, Ha N, Kim M. Simultaneous determination of L-ascorbic acid and dehydroascorbic acid in human plasma. Anal Methods 2015;7:9206. Search in Google Scholar
The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2019-0912).
©2020 Walter de Gruyter GmbH, Berlin/Boston